(104 days)
The Wielisa PR-3 ANCA Test Kit is an enzyme-linked immunosorbent assay (ELISA) for the detection and semi-quantitation of antibodies to Proteinase-3 (PR-3) in human sera. The assay is used to detect antibodies in a single serum specimen. The results of the assay are to be used as an aid to the diagnosis of Wegener's granulomatosis.
The Wielisa PR-3 ANCA Test Kit is an enzyme-linked immunosorbent assay (ELISA) for the detection and semi-quantitation of lgG antibodies to Proteinase-3 (PR-3) in human sera. The assay is used to detect antibodies in a single serum specimen. The results of the assay are to be used as an aid to the diagnosis of Wegener's granulomatosis. FOR IN VITRO DIAGNOSTIC USE.
The wells of the microtiter strips are coated with purified proteinase 3. During the first incubation, specific antibodies in diluted serum, will bind to the antigen coating,
The wells are then washed to remove unbound antibodies and other components. A conjugate of alkaline phosphatase-labeled antibodies to human IgG binds to the antibodies in the wells in this second incubation.
After a further washing step, detection of specific antibodies is obtained by incubation with substrate solution. The amount of bound antibodies correlates to the color intensity and is measured in terms of absorbance (optical density (OD)). The absorbance is then calculated against a calibrator curve and the results are given in arbitrary units.
The provided text is a summary of safety and effectiveness information for the Wielisa PR-3 ANCA Test Kit, a medical device cleared by the FDA in 1998. It primarily focuses on demonstrating substantial equivalence to a predicate device and presenting performance data from various studies.
Here's an attempt to extract the requested information, acknowledging that specific "acceptance criteria" (i.e., predefined thresholds for performance that the device must meet) are not explicitly stated as typical in modern regulatory submissions. Instead, the document presents the reported performance and implicitly expects these results to be sufficient to demonstrate substantial equivalence to the predicate.
Acceptance Criteria and Device Performance for Wielisa PR-3 ANCA Test Kit
1. Table of Acceptance Criteria and Reported Device Performance
As explicit, pre-defined acceptance criteria (e.g., "Sensitivity must be >90%") are not stated in the document, the "Reported Device Performance" column reflects what was achieved in the studies, which implicitly served as the basis for FDA clearance. The predicate device's performance is not detailed in this document, so direct comparison against a numerical benchmark from the predicate is not possible from the given text.
| Performance Metric | Implicit Acceptance Criteria (based on predicate equivalence) | Reported Device Performance (Wielisa PR-3 ANCA Test Kit) | Study Reference |
|---|---|---|---|
| Clinical Sensitivity (WG) | Sufficient for aid in diagnosis | 92.9% (95% CI: 86.7-99.0%) | Table 1 |
| Clinical Sensitivity (MP) | Sufficient for aid in diagnosis | 50.0% (95% CI: 36.1-63.9%) | Table 1 |
| Clinical Specificity (SLE) | Sufficient for aid in diagnosis | 97.4% (95% CI: 92.4-100%) | Table 1 |
| Clinical Specificity (RA) | Sufficient for aid in diagnosis | 100% (95% CI: 82.7-100%) | Table 1 |
| Clinical Specificity (GBM) | Sufficient for aid in diagnosis | 93.6% (95% CI: 87.3-99.8%) | Table 1 |
| Clinical Specificity (Normals) | Sufficient for aid in diagnosis | 100% (95% CI: 97.5-100%) | Table 1 |
| Relative Sensitivity (vs C-ANCA IFA) | Comparable to predicate device | 96.3% (95% CI: 92.1-100.0%) | Table 2 |
| Relative Specificity (vs C-ANCA IFA) | Comparable to predicate device | 91.9% (95% CI: 87.6-96.2%) | Table 2 |
| Relative Accuracy (vs C-ANCA IFA) | Comparable to predicate device | 93.4% (95% CI: 90.2-96.6%) | Table 2 |
| Relative Sensitivity (vs Alternate ELISA) | Comparable to predicate device | 100% (95% CI: 92.0-100%) | Table 3 |
| Relative Specificity (vs Alternate ELISA) | Comparable to predicate device | 97.5% (95% CI: 94.1-100%) | Table 3 |
| Relative Accuracy (vs Alternate ELISA) | Comparable to predicate device | 98.3% (95% CI: 95.9-100%) | Table 3 |
| Batch-to-Batch Mean CV | Acceptable for IVD use | 8.9% - 14.3% (for various samples) | Table 4 |
| Inter-Assay Mean CV | Acceptable for IVD use | Not clearly reported due to OCR error; likely ≤ 15% | Table 5 |
| Intra-Assay Mean CV | Acceptable for IVD use | Not clearly reported due to OCR error; likely ≤ 10% | Table 6 |
| Linearity (r value) | Demonstrated linear relationship | 0.811 - 0.945 (for various positive sera) | Table 7 |
2. Sample Size Used for the Test Set and the Data Provenance
- Clinical Sensitivity and Specificity (Table 1):
- Sample Size: 364 frozen retrospective human sera.
- Provenance: Retrospective, country of origin not specified, but the submission is from a Swedish company (Wieslab AB), implying European or international samples are possible.
- Relative Sensitivity and Specificity vs. C-ANCA IFA (Table 2):
- Sample Size: 245 frozen retrospective human sera.
- Provenance: Retrospective, country of origin not specified.
- Relative Sensitivity and Specificity vs. Alternate ELISA (Table 3):
- Sample Size: 120 frozen retrospective human sera.
- Provenance: Retrospective, country of origin not specified.
- Batch-to-batch variation (Table 4): 4 samples tested in duplicate across four different batches.
- Inter-assay precision (Table 5): 2 samples tested in duplicate across six different runs.
- Intra-assay precision (Table 6): 1 sample tested in 80 wells.
- Linearity (Table 7): 7 positive sera, serially diluted.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and the Qualifications of Those Experts
The document states that the sera for clinical sensitivity and specificity (Table 1) had "clinical characterization." However, it does not specify the number or qualifications of experts used to establish the ground truth (diagnosis of Wegener's granulomatosis, microscopic polyangiitis, etc.). It can be inferred that these diagnoses were established through standard clinical practice by medical professionals, but no details are provided regarding the adjudication or consensus process for these diagnoses in the context of this study.
For the comparative studies in Tables 2 and 3 (C-ANCA IFA and Alternate ELISA), the ground truth was the result of the comparator device. These are not human expert adjudications but rather comparisons against other laboratory tests.
4. Adjudication Method for the Test Set
- For the clinical characterization (Table 1), the document only states "clinical characterization." There is no explicit description of an adjudication method (e.g., 2+1, 3+1, none) for the diagnoses of the disease groups.
- For the comparative studies (Tables 2 and 3), the "ground truth" was established by the predicate or comparator assay (C-ANCA IFA or an alternate commercial ELISA). This is a direct comparison to a reference test, rather than human expert adjudication of images or clinical cases.
5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done
No, a multi-reader multi-case (MRMC) comparative effectiveness study was not done. This device is an in-vitro diagnostic (IVD) ELISA kit designed for laboratory use, not for direct human interpretation of medical images or complex clinical cases where MRMC studies are typically performed to assess human reader performance with and without AI assistance. The studies here compare the device's performance against clinical diagnoses or other established laboratory tests.
6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done
Yes, this entire submission represents a standalone performance evaluation. The Wielisa PR-3 ANCA Test Kit is a laboratory assay. The reported measurements of sensitivity, specificity, and precision are derived directly from the assay's output (absorbance readings converted to arbitrary units), without inherent human interpretation as part of the primary diagnostic output. Human intervention occurs at the level of performing the test and interpreting the final quantitative result within a clinical context, but the performance metrics presented are of the device itself.
7. The Type of Ground Truth Used
- Clinical Sensitivity & Specificity (Table 1): The ground truth was based on clinical characterization of the disease groups (Wegener's granulomatosis, microscopic polyangiitis, systemic lupus erythematosus, rheumatoid arthritis, anti-GBM nephritis, and healthy normals). This implies established clinical diagnoses, likely confirmed by a combination of clinical signs, symptoms, and other diagnostic tests, but not exclusively a single definitive "pathology" in all cases.
- Relative Sensitivity & Specificity (Tables 2 and 3): The ground truth was established by comparison to other laboratory tests: C-ANCA IFA (Table 2) and an alternate commercial ELISA (Table 3).
8. The Sample Size for the Training Set
The document does not provide information on a specific "training set" for the device. As an ELISA kit from 1998, it predates the widespread application of machine learning or AI models that require distinct training sets. The "development" of such a test would involve formulation, optimization of reagents, and establishment of cutoff values, rather than a machine learning training phase on a dedicated dataset. The data presented are performance evaluation data.
9. How the Ground Truth for the Training Set Was Established
Since no specific "training set" is mentioned (as the device is not an AI/ML diagnostic model), this question is not applicable in the context of the provided document. The "ground truth" for establishing the kit's parameters (e.g., calibrator values, cutoffs) would have been determined through internal development and validation processes using characterized samples, but these are not explicitly detailed as a "training set" in the provided text.
{0}------------------------------------------------
Summary of Safety and Effectiveness Information PR-3 ANCA Test Kit
FEB 17 1998
Wieslab AB Ideon Research Park S-223 70 Lund Sweden Contact person: Dr. Jorgen Wieslander Telephone: 46-46-182840 Date of preparation: Jan 19, 1998
【.
Description of Device: The Wielisa PR-3 ANCA Test Kit is an enzyme-linked immunosorbent 11. assay (ELISA) for the detection and semi-quantitation of lgG antibodies to Proteinase-3 (PR-3) in human sera. The assay is used to detect antibodies in a single serum specimen. The results of the assay are to be used as an aid to the diagnosis of Wegener's granulomatosis. FOR IN VITRO DIAGNOSTIC USE.
The wells of the microtiter strips are coated with purified proteinase 3. During the first incubation, specific antibodies in diluted serum, will bind to the antigen coating,
The wells are then washed to remove unbound antibodies and other components. A conjugate of alkaline phosphatase-labeled antibodies to human IgG binds to the antibodies in the wells in this second incubation.
After a further washing step, detection of specific antibodies is obtained by incubation with substrate solution. The amount of bound antibodies correlates to the color intensity and is measured in terms of absorbance (optical density (OD)). The absorbance is then calculated against a calibrator curve and the results are given in arbitrary units.
111. Predicate Device
The PR-3 ANCA test is substantially equivalent to the Immunoscan PR-3 ANCA ELISA Kit. Equivalence is demonstrated by the following comparative results:
{1}------------------------------------------------
Table 1. Clinical Sensitivity and Specificity A total of 364 frozen retrospective sera with clinical characterization were assayed. The following table summarizes the data.
| Control andDisease groups | Totalnumber | Negative<10 units | Equivocal10-20 units | Positive>20 units |
|---|---|---|---|---|
| Healthy Normals: | 120 | 120 | 0 | 0 |
| WG: | 70 | 5 | 0 | 65 |
| MP: | 55 | 26 | 3 | 26 |
| SLE: | 40 | 38 | 1 | 1 |
| RA: | 17 | 17 | 0 | 0 |
| Anti-GBM nephritis: | 62 | 58 | 0 | 4 |
GBM = glomerular basement membrane
WG = Wegener's granulomatosis, SLE = systemic lupus erythematosus
MP = microscopic polyangiitis
RA = rheumatoid arthritis
Clinical Sensitivity (Equivocal samples excluded from calculations)
| WG = 65/70 = 92.9% | 95% confidence interval = 86.7-99.0% |
|---|---|
| MP = 26/52 = 50.0% | 95% confidence interval = 36.1-63.9% |
Clinical Specificity (Equivocal samples excluded from calculations)
| SLE | = 38/39 | = 97.4% | 95% confidence interval = 92.4-100% |
|---|---|---|---|
| RA | = 17/17 | = 100% | *95% confidence interval = 82.7-100% |
| GBM | = 58/62 | = 93.6% | 95% confidence interval = 87.3-99.8% |
| Normals | = 120/120 | = 100% | *95% confidence interval = 97.5-100% |
The 95% confidence intervals were calculated using the normal method. *The 95% confidence intervals were calculated assuming one false positive.
{2}------------------------------------------------
Table 2 A total of 245 frozen retrospective sera were assayed on the Wielisa PR-3 ANCA ELISA and IFA. The following Table summarizes the relative sensitivity and specificity.
Relative Sensitivity and Specificity of the Wielisa PR-3 ANCA Compared to C-ANCA IFA
| Positive | Equivocal | Negative | Total | ||
|---|---|---|---|---|---|
| C-ANCAIFA | Positive | 78 | 0 | 3 | 81 |
| Negative | 13 | 3 | 148 | 164 | |
| Total | 91 | 3 | 151 | 245 |
Sera falling in the equivocal range were excluded from the following calculations
| 95% Confidence Interval | |||
|---|---|---|---|
| Relative Sensitivity | = 78/81 | = 96.3 % | 92.1 - 100.0 % |
| Relative Specificity | = 148/161 | = 91.9 % | 87.6 - 96.2 % |
| Relative Accuracy | = 226/242 | = 93.4 % | 90.2 - 96.6 % |
{3}------------------------------------------------
Table 3 A total of 120 frozen retrospective sera were assayed by the Wielisa PR-3 ANCA ELISA and by an alternate commercial ELISA. The following table summarizes the relative sensitivity and specificity of the assay.
Relative Sensitivity and Specificity of the Wielisa PR-3 Kit Compared to an Alternate ELISA .• -•
PR-3 Wielisa
| Positive | Equivocal | Negative | Total | ||
|---|---|---|---|---|---|
| Positive | 37 | 0 | 0 | 37 | |
| AlternateELISA | Equivocal | 1 | 0 | 1 | 2 |
| Negative | 2** | 0 | 79 | 81 | |
| Total | 40 | 0 | 80 | 120 |
Sera falling in the equivocal range were excluded from the following calculations
| 95% Confidence Interval | ||
|---|---|---|
| Relative Sensitivity | = 37/37 = 100 % | 92.0 - 100 %* |
| Relative Specificity | = 79/81 = 97.5 % | 94.1 - 100 % |
| Relative Accuracy | = 116/118 = 98.3 % | 95.9 - 100 % |
- One false negative was included in this caclulation.
** Both sera were from vasculitis patients
{4}------------------------------------------------
Table 4. Batch to batch variation.
Batch to batch variation was determined by testing 4 different samples in duplicate. Results were obtained for four different batches.
| Sample | Mean value | SD | CV % |
|---|---|---|---|
| 1 | 25 units | 2.3 | 9.1 |
| 2 | 29 units | 4.1 | 14.3 |
| 3 | 68 units | 8.7 | 12.7 |
| 4 | 76 units | 6.7 | 8.9 |
Table 5. Inter-assay precision.
Inter-assay precision was determined by testing 2 different samples in duplicate. Results were obtained for six different runs.
| the change on the collection in the contraction to the contraction and the collection of the color controlled inAND A LINE BOOK OF CHARREN FOR AND ANDREASample | I a sual manimal a minutesMean value | LE LEB LE LE RE MENSION AN FERRENCE CHARRIES CHARACT CHARACT CHARACT CHARACT CHARACT CHARACT CHARACT CHARACT CHARACT CHARACT CHARACT CHARACT CHARACT CHARACT CHARACT CHARACT CC | AT R CLEAR SECTIONALSTAR I IT AN ANNUAL CAR AN AN AN AN AN AN AN AN AN AN A CHANAL AND AND THE CHANALYCV %S | ------------ |
|---|---|---|---|---|
| 75 units | 1000 0 - | 1ﻟﻠﻘﺎﻧﻮﻥ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘ | ||
| 22 unitst------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | 1------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | t100 1 4 | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------MILLE LE LEAR MERICANAL PARKComments of Concession of Concession of Children Comments of Children Comments |
Table 6. Intra-assay precision.
Intra-assay precision was determined by testing one sample in 80 wells.
| .. No and more of the may be | THE THE THE THE FELLER FOR COLLECT COLLEGIAL COLLEGIAL COLLECTION COLLECTION COLLECTION COLLECTION COLLECTION COLLECTION COLLEGION100 Total Property. | LAND AN LINERAL CLAND LE LE E REAL LE LEBELLER BERE AND AND AND AND A BELL | ||
|---|---|---|---|---|
| . LE ENRECE E M LE MULA MOND BELLINER LE E REVIEWS! FINN BERThe former and consisted to the first from Party of the Arman Comments of the Children and Children and Children and Children and Children and Children and Children and Child------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | -100CANNOR COLOR COLLEGION CONSULT CONSULTION CONSULTION CONSULTION CONSULTION CONSULTION CONSULTION CONSULTION CONSULTION CONSULTION CONSULTION CONSULTION CONSULTION CONSULTION | - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - - 1 - - 1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - | 1CORRELLE OF CONSULTION COLLEGION CONSULTION CONSULTION CONSULTION CONSULTION CONSULTION CONSULTION CONSULTION CONSULTION CONSULTION CONSULTION CONSULTION CONSULTION CONSULTIO------------------------------------------------------------------------------------------------------------------------------------------------------------------------------A STORE STATE OF LEASE OF CANADA AN AND AND ALL |
Table 7. Linearity
.
The values were determined for serial two-fold dilutions of seven positive sera. The values were compared to log2 of dilution by standard linear regression. The data in Table 7 indicates that the assay has a linear relationship with serum dilution.
| Serum | Neat | 1:2 | 1:4 | 1:8 | 1:16 | 1:32 | 1:64 | r |
|---|---|---|---|---|---|---|---|---|
| 1 | 168 | 95 | 57 | 34 | 15 | 5 | 0.945 | |
| 2 | 84 | 43 | 23 | 13 | 5 | 0.942 | ||
| 3 | 230 | 80 | 50 | 31 | 19 | 7 | 0.851 | |
| 4 | 200 | 130 | 81 | 38 | 19 | 10 | 6 | 0.935 |
| 5 | 269 | 146 | 64 | 34 | 20 | 9.5 | 0.908 | |
| 6 | 276 | 75 | 46 | 26 | 12 | 8 | 0.811 | |
| 7 | 141 | 73 | 50 | 30 | 16 | 8 | 0.931 |
{5}------------------------------------------------
Image /page/5/Picture/1 description: The image is a black and white logo for the U.S. Department of Health & Human Services. The logo features a stylized image of an eagle with three profiles of human faces incorporated into its design. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" is arranged in a circular pattern around the eagle.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
WEISLAB AB William L. Boteler c/o IMMUNO PROBE, INC. 1306 Bailes Lane, Suite F Frederick, MD 21701
FFB 17 1998
Re: K974167 Trade Name: Wielisa PR-3 ANCA Test System Regulatory Class: II Product Code: MOB 82 Dated: January 19, 1998 January 20, 1998 Received:
Dear Mr. Boteler:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Requlations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
{6}------------------------------------------------
Page 2
Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. TO determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770)488-7655.
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll free number (800) 638-2041 or at (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html"
Sincerely yours,
Steven Putman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{7}------------------------------------------------
Page 1 of 1
510(k) Number: Not known ¥974167
Device Name: Wielisa PR-3 ANCA Test Kit
Indications For Use: The Wielisa PR-3 ANCA Test Kit is an enzyme-linked immunosorbent assay (ELISA) for the detection and semi-quantitation of antibodies to Proteinase-3 (PR-3) in human sera. The assay is used to detect antibodies in a single serum specimen. The results of the assay are to be used as an aid to the diagnosis of Wegener's granulomatosis.
Peter E. Makin
(Division Sign-Off) (Division of Clinical Laboratory Devices LG 74 16
PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use V (Per 21 CFR 801.109)
OR
Over-The Counter Use (Optional Format 1-2-96)
§ 866.5660 Multiple autoantibodies immunological test system.
(a)
Identification. A multiple autoantibodies immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the autoantibodies (antibodies produced against the body's own tissues) in serum and other body fluids. Measurement of multiple autoantibodies aids in the diagnosis of autoimmune disorders (disease produced when the body's own tissues are injured by autoantibodies).(b)
Classification. Class II (performance standards).